Enterprise Value
-13.38M
Cash
24.01M
Avg Qtr Burn
-5.115M
Short % of Float
0.18%
Insider Ownership
0.44%
Institutional Own.
4.54%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMNN-001 (GEN-1) +/- bevacizumab Details Ovarian cancer, Cancer | Phase 1/2 Data readout | |
ThermoDox Details Cancer, Liver cancer | Failed Discontinued |